度他雄胺与非那雄胺哪个效果好？

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

Dutasteride may be more effective in treating benign prostatic hyperplasia and androgenetic alopecia in men.

Both drugs, dutasteride and finasteride, can be used to treat benign prostatic hyperplasia and male androgenic alopecia. Dutasteride and finasteride are inhibitors of 5-alpha-reductase, which inhibits the conversion of testosterone into dihydrotestosterone. Dutasteride inhibits both type I and type II 5-alpha-reductase enzymes, whereas finasteride inhibits only type II enzymes. Since both isoenzymes are present in hair follicles, dutasteride may be more effective than finasteride.

Dutasteride and finasteride

The 5-alpha-reductase inhibitors finasteride and dutasteride are commonly used to treat androgenic alopecia and benign prostatic hyperplasia. These drugs are effective in reducing levels of dihydrotestosterone, the primary androgen responsible for both conditions.

But finasteride and dutasteride have also been shown to increase the incidence of sexual dysfunction, namely impotence, decreased libido, and ejaculation disorders.

Comparison of the efficacy of dutasteride and finasteride in male androgenic alopecia

Androgenic alopecia is a common disease characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by 5-alpha-reductase is the underlying pathogenesis. Dutasteride is a synthetic 4-azasteroid that is a selective and competitive inhibitor of 5-alpha-reductase type 1 and type 2 isoenzymes.

Finasteride and minoxidil are the only drugs approved to treat androgenic alopecia. It has been shown to be effective in androgenetic alopecia in multiple randomized, double-blind, placebo-controlled trials.

Purpose: The purpose of this study was to compare the efficacy, safety, and tolerability of dutasteride and finasteride in the treatment of androgenic alopecia in men.

Methods: Male patients aged 18 to 40 years with androgenic alopecia were randomized to receive 0.5 mg dutasteride or 1 mg finasteride daily for 24 weeks. The primary efficacy variable was target area hair count (thickness and sparseness) assessed by modified trichography and global photography by blinded and unblinded investigators. Secondary efficacy variables were subjective assessments using prespecified questionnaires. Patients were assessed for side effects monthly.

Results: 90 male patients with androgenic alopecia were included in the study. The increase in the number of total hairs per centimeter representing new growth was significantly higher in the dutasteride group compared with the finasteride group. The number of fine hairs per centimeter was reduced in the dutasteride group, indicating a significantly higher reversal of miniaturization. Both groups showed a similar side effect profile, with sexual dysfunction being the most common and reversible side effect.

It can be concluded that dutasteride and finasteride may be more effective in treating male androgenic alopecia.

Like finasteride, dutasteride is now becoming a popular treatment option for men with androgenic alopecia, as various randomized controlled studies and meta-analyses have shown favorable responses. Furthermore, in most of these studies, dutasteride was found to have a better adverse effect profile than finasteride.

Therefore, dutasteride may become the drug of choice for the treatment of male androgenic alopecia in the near future.

Dutasteride versus finasteride in benign prostatic hyperplasia

Objective: To investigate differences in the risk of benign prostatic hyperplasia (BPH)-related hospitalizations for surgical and non-surgical reasons and of new prostate cancer (PCa) diagnoses in patients taking finasteride or dutasteride.

Methods: Retrospective cohort study using data from administrative database record linkage. Men aged ≥40 years who received at least 10 packs/year of prescriptions between January 1, 2004, and December 31, 2004 were included in the study and followed for 5 years. The relevance of the results was assessed using a multiple Cox proportional hazards model.

Results: 8132 patients were identified. The overall incidence rates of BPH hospitalization and BPH-related surgery were 21.05 and 20.97 per 1,000 person-years, respectively.

The incidence of these two events was statistically significantly lower in the dutasteride group compared with the finasteride group: the incidence of hospitalization for benign prostatic hyperplasia was 16.07 vs. 21.76, and the incidence of benign prostatic hyperplasia-related surgery was 15.91 vs. 21.69. The incidence of new prostate cancer was also lower in the dutasteride group [8.34 vs. 10.25].

Dutasteride is associated with a reduction in hospitalizations related to benign prostatic hyperplasia. Matched analysis confirmed that dutasteride reduces the risk of benign prostatic hyperplasia-related surgery.

Conclusion: These findings suggest that the clinical effects of dutasteride and finasteride may differ. Patients receiving dutasteride appear to be less likely to experience hospitalization related to prostatic hyperplasia.

Summary

Both dutasteride and finasteride can be used to treat benign prostatic hyperplasia and male androgenic alopecia, but dutasteride may be better in efficacy. However, due to the different personal circumstances and conditions of each patient, the efficacy varies from person to person. It is recommended that patients choose appropriate drug treatment under the guidance of a doctor to ensure that the drug can fully exert its therapeutic effect.